---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-24-058812"
form_type: "8-K"
ticker: null
cik: "0001764974"
company_name: "Turnstone Biologics Corp."
filed_at: "2024-05-13T23:59:59+00:00"
generated_at: "2026-06-02T02:31:54.046930+00:00"
event_type: "earnings"
sentiment: "negative"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Turnstone Biologics Q1 2024 net loss $19.6M; cash $77.8M funds into Q3 2025

## Summary
- Net loss of $19.6M vs $0.1M net income in Q1 2023, no collaboration revenue recognized.
- Cash and short-term investments $77.8M as of March 31, 2024; expected to fund operations into Q3 2025.
- R&D expenses $15.8M, flat YoY; G&A expenses $4.9M, up from $4.0M due to public company costs.
- Secured $20M non-dilutive revolving credit facility from Banc of California in April 2024.
- Appointed William Waddill to Board; Patrick Machado stepped down. TIDAL-01 Phase 1 update expected mid-year.

## SEC filing metadata
- accession: 0000950170-24-058812
- form_type: 8-K
- cik: 0001764974
- company_name: Turnstone Biologics Corp.
- filed_at: 2024-05-13T23:59:59+00:00
- event_type: earnings
- sentiment: negative
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1764974/000095017024058812/0000950170-24-058812-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1764974/000095017024058812/tsbx-20240513.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-24-058812
- JSON: https://secwatch.observer/filing/0000950170-24-058812.json
- Plain text: https://secwatch.observer/filing/0000950170-24-058812.txt

## Key facts
- Earnings Releases
  Turnstone Biologics Corp. reported first quarter ended March 31, 2024 results: net income Net loss was $19.6 million.
  - Period: first quarter ended March 31, 2024
  - Net income: Net loss was $19.6 million
  - Result: reported results
  source text: On May 13, 2024, Turnstone Biologics Corp. (the “Company”) issued a press release announcing financial results for the fiscal quarter ended March 31, 2024
  evidence_url: https://www.sec.gov/Archives/edgar/data/1764974/000095017024058812/0000950170-24-058812-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.